Targeted Therapy

Data shows that NST-628, a new “molecular glue” drug targeting the RAF/MEK pathway, may offer a promising treatment for patients with NRAS and BRAF class II/III mutant melanoma, who currently have few targeted therapy options. In an early phase clinical trial involving heavily pretreated patients, NST-628 showed strong anti-cancer activity. In melanoma patients, it achieved […]

New research shows that combining comprehensive tumor profiling with blood-based DNA monitoring can guide treatment for most patients with breast and colorectal cancer. Using advanced genomic testing alongside circulating tumor DNA (ctDNA) analysis, researchers found that 98% of patients had at least one actionable genetic alteration, and over half had markers linked to approved targeted

The phase 3 AFFIRM-205 trial shows that the combination of afuresertib and fulvestrant significantly improves outcomes in patients with advanced HR-positive HER2-negative breast cancer with PIK3CA/AKT1/PTEN pathway alterations. Many of these patients had already developed resistance after prior treatments, including CDK4/6 inhibitors. The study met its main goal, showing that the combination delayed disease progression

Researchers are adapting CAR T-cell therapy, originally developed for cancer treatment, to treat autoimmune diseases such as lupus, multiple sclerosis (MS), and rheumatoid arthritis. The approach works by collecting a patient’s T cells and genetically modifying them to target and destroy overactive B cells, which are responsible for mistakenly attacking healthy tissues in autoimmune conditions.

Orca-T and Orca-Q are emerging cell therapies that may improve outcomes in blood cancer transplants while reducing graft-versus-host disease (GVHD), according to Sagar S. Patel of Huntsman Cancer Institute. Orca-T is being tested in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), particularly older or frail individuals who cannot tolerate intensive treatment. A

Pancreatic cancer treatment is beginning to shift from traditional chemotherapy to a more personalized approach, according to a new review. Although survival rates remain low, recent advances targeting genetic mutations and the tumor environment are starting to improve outcomes. For most patients, combination chemotherapy is still the standard treatment. Regimens like FOLFIRINOX or NALIRIFOX are

A large analysis of more than 2,300 patients from nine major clinical trials has found that race does not affect how well CAR T-cell therapy works for people with B-cell lymphoma. Instead, patient outcomes depend mainly on clinical factors such as overall health and how advanced the disease is at the start of treatment. When

A new study highlights dinaciclib as a promising treatment for Adult T-cell Leukemia/Lymphoma, an aggressive cancer caused by the Human T-lymphotropic Virus 1 with very poor survival outcomes. Researchers found that ATL cells rely heavily on anti-apoptotic proteins to avoid cell death, largely driven by viral proteins that keep these survival pathways active. Dinaciclib works by

A new analysis shows that adding local consolidative therapy (LCT), such as radiation, to osimertinib can significantly improve outcomes for patients with EGFR-mutated non–small cell lung cancer. Patients who received both LCT and osimertinib had longer disease control, with progression-free survival reaching 25.3 months compared with 17.5 months for those on osimertinib alone. Higher-dose radiation

A study shows that adding the bispecific antibody glofitamab to CAR T-cell therapy can improve outcomes for patients with relapsed or hard-to-treat B-cell lymphomas. CAR T-cell therapy is already widely used, but many patients relapse because cancer cells can hide from treatment, the CAR T-cells lose strength over time, or the tumor environment blocks the